Table 1.
Cetuximab and trastuzumab staining intensity in different xenografts.
| Cell line | Monoclonal antibody | Dose (mg) | Time after injection | Staining Intensity at 20 μm from blood vessels (mean IU) ± SEM | Staining Intensity at 100 μm from blood vessels (mean IU) ± SEM | Gradient of Staining Intensity (IU/μm) |
|---|---|---|---|---|---|---|
| A431 | Cetuximab | 0.01 | 24 h | 26.8 ± 2.0 | 12.7 ± 1.4 | -0.18 |
| 0.05 | 24 h | 34.3 ± 4.8 | 24.5 ± 0.4 | -0.12 | ||
| 1.0 | 30 min | 36.1 ± 0.2 | 21.2 ± 1.3 | -0.19 | ||
| 1.0 | 4 h | 34.9 ± 2.7 | 25.0 ± 2.3 | -0.12 | ||
| 1.0 | 24 h | 35.9 ± 3.5 | 34.7 ± 3.9 | -0.02 | ||
| 1.0 | 48 h | 36.1 ± 1.2 | 37.8 ± 1.8 | -0.02 | ||
| MDA-MB-231 | Cetuximab | 0.01 | 24 h | 7.0 ± 0.6 | 7.4 ± 1.1 | 0.01 |
| 0.05 | 24 h | 7.6 ± 0.8 | 6.9 ± 0.9 | -0.01 | ||
| 0.1 | 24 h | 15.0 ± 2.8 | 18.5 ± 2.8 | 0.04 | ||
| 0.5 | 15 min | 6.9 ± 1.5 | 6.3 ± 0.7 | -0.01 | ||
| 0.5 | 30 min | 8.3 ± 5.7 | 5.7 ± 3.7 | -0.03 | ||
| 0.5 | 1 h | 18.9 ± 1.1 | 17.0 ± 1.1 | -0.02 | ||
| 0.5 | 2 h | 19.1 ± 3.9 | 14.0 ± 2.9 | -0.06 | ||
| 0.5 | 4 h | 20.8 ± 1.5 | 24.3 ± 1.5 | 0.04 | ||
| 0.5 | 6 h | 17.6 ± 4.0 | 20.3 ± 4.6 | 0.03 | ||
| 0.5 | 24 h | 16.7 ± 2.2 | 20.7 ± 1.6 | 0.05 | ||
| 1.0 | 24 h | 17.3 ± 2.7 | 21.2 ± 2.5 | 0.05 | ||
| 231-H2N | Trastuzumab | 0.1 | 2 h | 16.8 ± 2.1 | 12.7 ± 1.8 | -0.05 |
| 0.3 | 30 min | 19.4 ± 0.9 | 16.6 ± 1.3 | -0.04 | ||
| 0.3 | 2 h | 23.0 ± 1.6 | 19.9 ± 2.1 | -0.04 | ||
| 0.3 | 4 h | 24.0 ± 2.1 | 18.5 ± 3.0 | -0.07 | ||
| 0.3 | 24 h | 29.0 ± 1.0 | 27.3 ± 0.8 | -0.02 | ||
| 1.0 | 2 h | 27.0 ± 1.3 | 26.2 ± 1.4 | -0.01 | ||
Staining intensity of cetuximab and trastuzumab at 20 μm and 100 μm from blood vessels in A431, MDA-MB-231 and 231-H2N xenografts. Gradient of staining intensity is shown.